ClinicalTrials.gg
RecruitingNCT06987903CAPS-OBUpdated Oct 13, 2026

Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Surgery

An interventional study of Pre- and post-operative physical exercise programme and Pre- and post-operative respiratory physiotherapy in Bariatric Surgery and Physical Activity, Obesity/Therapy and Bariatric Surgery Complications, sponsored by Fundacin Biomedica Galicia Sur. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionObesityRegistry: Motor ActivityReclassifiedWhy we changed it
Registry
Motor Activity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. Motor Activity is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundacin Biomedica Galicia Sur · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.

Planned enrollment
159th of 332
132 · median 124
Started
2025
with 51 others
No phase
220 of 390
41 open now
Primary completion
2028-09
later than 115 of 133 live
Registered
281st of 390
by date

Among the 390 studies in Obesity with a site in Spain, this one is the 159th largest by planned enrollment of the 332 interventional ones that give a count, is one of 52 that started in 2025, is one of 220 with no phase, reaches primary completion later than 115 of the 133 other live ones, and was the 281st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:

90 more — sign in →

All 95 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Obesity with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to see the impact of a physical exercise programme and respiratory physiotherapy before and after bariatric surgery in obese patients. The main questions it aims to answer are:

Could it help to avoid decompensation of underlying diseases? Could it reduce the risks associated with the intervention and the number of adverse effects during the postoperative period? Could it reduce the number of patients and encourage early discharge? How does exercise affect epigenetics in obese patients undergoing bariatric surgery? Can we correlate epigenectic markers obtained from tissue obtained by invasive procedures such as fat or muscle to those obtained by non-invasive methods such as blood and saliva samples? How does exercise affect the hepatic tissue in obese patients undergoing bariatric surgery? And are the any predictive markers in pre-exercise samples that can correlate with the evolution of liver diseases such asl NALFD or NASH?

Researchers will compare one group of subjects performing the exercise programme and respiratory physiotherapy and anoher group performing the normal activities of routine clinical practice.

Participants, who are on the surgical waiting list for bariatric surgery, will be assigned to one of the two groups. Participants in group 2 will follow the normal procedure before and after surgery. Participants in group 1 will be asked to do a exercise programme and respiratory physiotherapy before and after surgery.

03

Conditions studied

  • Bariatric Surgery and Physical Activity
  • Obesity/Therapy
  • Bariatric Surgery Complications
  • Bariatric Patients

Browse trials for

Keywords

  • Bariatric surgery
  • Obesity
  • Respiratory physiotherapy
  • Exercise programme
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 132 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Fundacin Biomedica Galicia Sur is the lead sponsor of 28 studies on the registry; 7 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Motor Activity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing bariatric surgery at the General and Digestive Surgery Department of the Álvaro Cunqueiro Hospital in Vigo.
  • Be over 18 and under 69 years old.
  • Sign the to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patient's refusal to enter the study.
  • Inability to comprehend participation in a study.
  • Urgent interventions.
  • Patients undergoing combined surgery with another surgical service.
  • Patients who cannot read and write or are dependent on a legal representative.
  • Patients on treatment for diabetes with GLP-1 agonists (glucagon-like peptide type 1 agonists) and/or SGLT2 inhibitors (sodium-glucose cotransporter type 2 inhibitors) whose dose is not stable in the last 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Specific pre- and post-operative physical exercise and respiratory physiotherapy programme.

    Procedure: Pre- and post-operative physical exercise programme · Procedure: Pre- and post-operative respiratory physiotherapy

  • No intervention
    Arm 2

    Usual pre- and post-operative procedure without a specific exercise programme.

Interventions

  • ProcedurePre- and post-operative physical exercise programme

    Pre- and post-operative physical exercise programme during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants. A program will be designed according to the needs and preferences of the individual and will include: Aerobic exercise: Activities that mobilize large muscle groups for prolonged periods of time.Walking, running at a slow or moderate pace (especially on a treadmill), cycling, cycloergometer, etc. In addition, due to the characteristics of the patients, the recommended exercises will be of low impact. Strength exercise: Exercises of large muscle groups with intensities adapted to patients using body weight or elastic bands of different resistances. Flexibility exercise: Stretching exercises will be included during the warm-up and cool-down of each exercise session of the program.

  • ProcedurePre- and post-operative respiratory physiotherapy

    Pre- and post-operative respiratory physiotherapy during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants. Breathing exercises: Abdomino-diaphragmatic respiratory control exercises, costo-diaphragmatic respiratory control exercises, costo-diaphragmatic breathing control exercises, exercises with costal expansion and arm elevation and breathing exercises with pursed lips in different positions. Incentive spirometry: Incentive spirometry with the performance of slow, deep breaths in a volumetric incentive device.

07

What researchers measure

Primary outcomes

  1. Total weight loss

    \[(Preoperative weight - Weight at 8 weeks post-operative) / Preoperative weight\]\*100

    Time frame: From enrollment to the end of intervention at 8 weeks

  2. Waist circumference

    Waist circumference measured in cm

    Time frame: From enrollment to the end of intervention at 8 weeks

  3. Sex (at birth)

    Time frame: Once at the inclusion

Secondary outcomes

  1. Comorbidities

    It will indicate which comorbidities the patient has from a list with the following options: Hypertension, type 2 diabetes mellitus, dyslipidaemia, COPD, OSAS / OSHS, cardiovascular, GERD, arthropathy, infertility, neoplasias, psoriasis, hepatics, deppresion.

    Time frame: 4 weeks before bariatric surgery

  2. Age

    Age in years

    Time frame: 4 weeks before bariatric surgery

  3. Concomitant medication

    It will indicate which concomitant medication the patient has from a list with the following options: Anticoagulant, antiaggregant, stable GLP1 agonist.

    Time frame: 4 weeks before bariatric surgery

  4. Active smoking

    Yes/No

    Time frame: 4 weeks before bariatric surgery

  5. Alcohol consumption

    Alcohol consumption in UBEs or Units of alcohol

    Time frame: 4 weeks before bariatric surgery

  6. Previous abdominal surgeries

    Yes/No

    Time frame: 4 weeks before bariatric surgery

  7. Previous bariatric interventions

    Yes/No

    Time frame: 4 weeks before bariatric surgery

  8. Weight at inclusion

    Kilograms

    Time frame: 4 weeks before bariatric surgery

  9. Height at inclusion

    Metres

    Time frame: 4 weeks before bariatric surgery

  10. Impedanciometry

    Fat mass, bone mass, muscle mass, intracellular and extracellular water mass.

    Time frame: 4 weeks before bariatric surgery

  11. ASA Score

    Time frame: 4 weeks before bariatric surgery

  12. Baseline O2 Saturation

    %

    Time frame: 4 weeks before bariatric surgery

  13. Blood glucose

    mg/dL

    Time frame: From enrollment to the end of intervention at 8 weeks

  14. Haemoglobin A1c

    % Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  15. Total protein

    g/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  16. Albumin

    g/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  17. Pre-Albumin

    mg/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  18. Cholesterol

    mg/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  19. Triglycerides

    mg/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  20. HDL Cholesterol

    mg/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  21. LDL Cholesterol

    mg/dL

    Time frame: From enrollment to the end of intervention at 8 weeks

  22. AST (GOT)

    UI/L Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  23. ALT (GPT)

    UI/L Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  24. GGT

    UI/L Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  25. Alkaline phosphatase

    UI/L Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  26. LDH

    UI/L Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  27. Iron

    µg/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  28. Transferrin

    µg/dL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  29. Transferrin saturation rate

    % Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  30. Ferritin

    ng/mL

    Time frame: From enrollment to the end of intervention at 8 weeks

  31. Vitamin B12

    pg/mL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  32. Folic acid

    ng/mL

    Time frame: From enrollment to the end of intervention at 8 weeks

  33. Lactate

    mmol/L Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  34. Exerkines

    ng/mL Myokines and exerkines, lactate, insulin. Oxidative stress markers. DNA methylation profile and gene expression. Lipidomic and metabolomic profile.

    Time frame: From enrollment to the end of intervention at 8 weeks

  35. Myokines

    ng/mL

    Time frame: From enrollment to the end of intervention at 8 weeks

  36. IL

    pg/mL

    Time frame: From enrollment to the end of intervention at 8 weeks

  37. Grip strength dynamometry

    Time frame: From enrollment to the end of intervention at 8 weeks

  38. Goniometry

    Joint goniometry of the main joints of the extremities (shoulder, elbow, wrist, hip, knee, ankle) will be performed to rule out important joint limitations that also require some type of adaptation in the exercise program.

    Time frame: 4 weeks before bariatric surgery

  39. Sit to stand Test

    5 repetitions

    Time frame: From enrollment to the end of intervention at 8 weeks

  40. 6' walk test

    Distance walked and Vo2max estimation

    Time frame: From enrollment to the end of intervention at 8 weeks

  41. Walking speed test

    Time to cover 4 metres at usual pace.

    Time frame: From enrollment to the end of intervention at 8 weeks

  42. IPAQ

    International Physical Activity Questionnaire. High, moderate, low.

    Time frame: From enrollment to the end of intervention at 8 weeks

  43. ARISCAT

    Score for Postoperative Pulmonary Complications. From 0 (Low risk) to 123 points (High risk)

    Time frame: 4 weeks before bariatric surgery

  44. Oral tolerance

    (YES/NO)

    Time frame: Immediate postoperative period up to 12 hours after surgery

  45. Beginning of standing

    (YES/NO)

    Time frame: Immediate postoperative period up to 12 hours after surgery

  46. Urinary catheterisation

    (YES/NO)

    Time frame: Immediate postoperative period up to 12 hours after surgery

  47. Use of respiratory incentive

    (YES/NO)

    Time frame: The first day after surgery

  48. EVA of level of subjetive pain felt

    Visual analog scale from zero (0) to ten (10). Zero being no pain at all, ten being the worst pain imaginable

    Time frame: The first, second and third day after surgery

  49. Morbidity/complications

    (YES/NO)

    Time frame: The fourth day after surgery

  50. Days from post-operative period to discharge

    Days

    Time frame: The fourth day after surgery

  51. Emergency attendance in the first 30 days from discharge

    (YES/NO)

    Time frame: 8 weeks after discharge

  52. Re-admission in General and Digestive Surgery Department

    (YES/NO)

    Time frame: 8 weeks after discharge

  53. Re-intervention during re-admission

    (YES/NO)

    Time frame: 8 weeks after discharge

  54. Average daily steps

    Time frame: 8 weeks after discharge

  55. Adverse events during exercise

    Dizziness, pain, dyspnoea

    Time frame: From enrollment to the end of intervention at 8 weeks

  56. Compliance with exercise programme.

    Only in arm 1 participants. (0%, \<50%, \>50 - \<100%, 100%)

    Time frame: 8 weeks after discharge

  57. EuroQol 5D (Quality of Life Questionnaire)

    Quality of Life Questionnaire. From 0 to 100, where 100 is the best possible health state.

    Time frame: From enrollment to the end of intervention at 8 weeks

  58. Suter oral tolerance test

    Questionnaire for assessment of food tolerance after bariatric surgery. From 1 to 27, where 27 is the best food tolerance.

    Time frame: 8 weeks after discharge

  59. Surgical Variable: Kind of approach

    It will indicate which kind of approach from a list with the following options: Simple laparoscopy, 3D Laparoscopy, Single port, Reduced ports, Assisted robotics (DaVinci Xi), Laparotomy

    Time frame: In bariatric surgery

  60. Surgical Variable: number of trocars

    Number of trocars

    Time frame: In bariatric surgery

  61. Surgical Variable: surgical technique

    It will indicate which surgical technique from a list with the following options: Gastric bypass, Vertical gastrectomy, Nissen-Sleeve, SADI, Other

    Time frame: In bariatric surgery

  62. Surgical Variable: associated surgery

    (YES/NO)

    Time frame: In bariatric surgery

  63. Surgical Variable: revision surgery

    (YES/NO)

    Time frame: In bariatric surgery

  64. Surgical Variable: opioid-free anesthetic protocol (OFA)

    (YES/NO)

    Time frame: In bariatric surgery

  65. Surgical Variable: Intraoperative pneumatic compression stockings

    (YES/NO)

    Time frame: In bariatric surgery

  66. Surgical Variable: urinary catheterisation

    (YES/NO)

    Time frame: In bariatric surgery

  67. Surgical Variable: intra-abdominal drainage

    (YES/NO)

    Time frame: In bariatric surgery

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2028, 40 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 40 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
May 23, 2025
StartActual
May 7, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06987903
Lead sponsor
Fundacin Biomedica Galicia Sur
Responsible party
Marta López Otero (Principal Investigator, Fundacin Biomedica Galicia Sur) — Principal investigator
First posted
May 23, 2025
Start date
May 7, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion